Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses

Elisabeth M. Paietta, Janet Andersen, Janis Racevskis, Robert Gallagher, John Bennett, Jorge Yunis, Peter Cassileth, Peter H. Wiernik

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Expression of P-glycoprotein (Pgp), the product of the multidrug resistance (MDR1) gene, detected by flow cytometric analysis of the binding of antibody 4E3.16, was found on significantly fewer leukemic cells in 35 adult patients with de novo acute promyelocytic leukemia (APL) (mean 14.8%, median 7%) than in 184 patients with non-APL acute myeloid leukemia (AML) at diagnosis (mean 28.3%, median 18%) (p=0.0038). APL was diagnosed based on morphology, the detection of t(15;17) and of the chimeric fusion transcript PMI/RARα by PCR. To further substantiate low MDR1 expression in APL, we studied cells from 11 APL patients at the molecular and functional level in comparison to 48 non-APL cases. The diagnosis of APL was associated with the absence of Pgp function by the rhodamine efflux assay (p=0.0001). Furthermore, MDR1-specific transcript levels, determined by quantitative PCR with two distinct sets of primers, were significantly lower in mononuclear cells from the APL than the other AML cases (p=0.013). The frequency of leukemic cells positive for CD34, an antigen presumably associated with Pgp expression in AML, was significantly lower in APL than other AMLs (p=0.0001). In contrast to non-APL leukemias, those few cases of CD34 strongly positive APL neither expressed Pgp nor contained significant MDR1 transcript levels. Low expression of Pgp by APL cells may provide the biologic basis for the high sensitivity of this leukemia subtype to chemotherapeutic agents in vivo.

Original languageEnglish (US)
Pages (from-to)968-973
Number of pages6
JournalLeukemia
Volume8
Issue number6
StatePublished - Jun 1994

Fingerprint

Acute Promyelocytic Leukemia
P-Glycoprotein
Acute Myeloid Leukemia
Leukemia
CD34 Antigens
MDR Genes
Polymerase Chain Reaction
Rhodamines
Gene Flow
Antibodies

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia : Immunological, molecular and functional analyses. / Paietta, Elisabeth M.; Andersen, Janet; Racevskis, Janis; Gallagher, Robert; Bennett, John; Yunis, Jorge; Cassileth, Peter; Wiernik, Peter H.

In: Leukemia, Vol. 8, No. 6, 06.1994, p. 968-973.

Research output: Contribution to journalArticle

Paietta, Elisabeth M. ; Andersen, Janet ; Racevskis, Janis ; Gallagher, Robert ; Bennett, John ; Yunis, Jorge ; Cassileth, Peter ; Wiernik, Peter H. / Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia : Immunological, molecular and functional analyses. In: Leukemia. 1994 ; Vol. 8, No. 6. pp. 968-973.
@article{1f774e0083ec4662b0f3f175c503f89c,
title = "Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses",
abstract = "Expression of P-glycoprotein (Pgp), the product of the multidrug resistance (MDR1) gene, detected by flow cytometric analysis of the binding of antibody 4E3.16, was found on significantly fewer leukemic cells in 35 adult patients with de novo acute promyelocytic leukemia (APL) (mean 14.8{\%}, median 7{\%}) than in 184 patients with non-APL acute myeloid leukemia (AML) at diagnosis (mean 28.3{\%}, median 18{\%}) (p=0.0038). APL was diagnosed based on morphology, the detection of t(15;17) and of the chimeric fusion transcript PMI/RARα by PCR. To further substantiate low MDR1 expression in APL, we studied cells from 11 APL patients at the molecular and functional level in comparison to 48 non-APL cases. The diagnosis of APL was associated with the absence of Pgp function by the rhodamine efflux assay (p=0.0001). Furthermore, MDR1-specific transcript levels, determined by quantitative PCR with two distinct sets of primers, were significantly lower in mononuclear cells from the APL than the other AML cases (p=0.013). The frequency of leukemic cells positive for CD34, an antigen presumably associated with Pgp expression in AML, was significantly lower in APL than other AMLs (p=0.0001). In contrast to non-APL leukemias, those few cases of CD34 strongly positive APL neither expressed Pgp nor contained significant MDR1 transcript levels. Low expression of Pgp by APL cells may provide the biologic basis for the high sensitivity of this leukemia subtype to chemotherapeutic agents in vivo.",
author = "Paietta, {Elisabeth M.} and Janet Andersen and Janis Racevskis and Robert Gallagher and John Bennett and Jorge Yunis and Peter Cassileth and Wiernik, {Peter H.}",
year = "1994",
month = "6",
language = "English (US)",
volume = "8",
pages = "968--973",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia

T2 - Immunological, molecular and functional analyses

AU - Paietta, Elisabeth M.

AU - Andersen, Janet

AU - Racevskis, Janis

AU - Gallagher, Robert

AU - Bennett, John

AU - Yunis, Jorge

AU - Cassileth, Peter

AU - Wiernik, Peter H.

PY - 1994/6

Y1 - 1994/6

N2 - Expression of P-glycoprotein (Pgp), the product of the multidrug resistance (MDR1) gene, detected by flow cytometric analysis of the binding of antibody 4E3.16, was found on significantly fewer leukemic cells in 35 adult patients with de novo acute promyelocytic leukemia (APL) (mean 14.8%, median 7%) than in 184 patients with non-APL acute myeloid leukemia (AML) at diagnosis (mean 28.3%, median 18%) (p=0.0038). APL was diagnosed based on morphology, the detection of t(15;17) and of the chimeric fusion transcript PMI/RARα by PCR. To further substantiate low MDR1 expression in APL, we studied cells from 11 APL patients at the molecular and functional level in comparison to 48 non-APL cases. The diagnosis of APL was associated with the absence of Pgp function by the rhodamine efflux assay (p=0.0001). Furthermore, MDR1-specific transcript levels, determined by quantitative PCR with two distinct sets of primers, were significantly lower in mononuclear cells from the APL than the other AML cases (p=0.013). The frequency of leukemic cells positive for CD34, an antigen presumably associated with Pgp expression in AML, was significantly lower in APL than other AMLs (p=0.0001). In contrast to non-APL leukemias, those few cases of CD34 strongly positive APL neither expressed Pgp nor contained significant MDR1 transcript levels. Low expression of Pgp by APL cells may provide the biologic basis for the high sensitivity of this leukemia subtype to chemotherapeutic agents in vivo.

AB - Expression of P-glycoprotein (Pgp), the product of the multidrug resistance (MDR1) gene, detected by flow cytometric analysis of the binding of antibody 4E3.16, was found on significantly fewer leukemic cells in 35 adult patients with de novo acute promyelocytic leukemia (APL) (mean 14.8%, median 7%) than in 184 patients with non-APL acute myeloid leukemia (AML) at diagnosis (mean 28.3%, median 18%) (p=0.0038). APL was diagnosed based on morphology, the detection of t(15;17) and of the chimeric fusion transcript PMI/RARα by PCR. To further substantiate low MDR1 expression in APL, we studied cells from 11 APL patients at the molecular and functional level in comparison to 48 non-APL cases. The diagnosis of APL was associated with the absence of Pgp function by the rhodamine efflux assay (p=0.0001). Furthermore, MDR1-specific transcript levels, determined by quantitative PCR with two distinct sets of primers, were significantly lower in mononuclear cells from the APL than the other AML cases (p=0.013). The frequency of leukemic cells positive for CD34, an antigen presumably associated with Pgp expression in AML, was significantly lower in APL than other AMLs (p=0.0001). In contrast to non-APL leukemias, those few cases of CD34 strongly positive APL neither expressed Pgp nor contained significant MDR1 transcript levels. Low expression of Pgp by APL cells may provide the biologic basis for the high sensitivity of this leukemia subtype to chemotherapeutic agents in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0028270713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028270713&partnerID=8YFLogxK

M3 - Article

C2 - 7516029

AN - SCOPUS:0028270713

VL - 8

SP - 968

EP - 973

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 6

ER -